Additional Information Patent Expiries of Key Marketed Products Patents covering our products are or may be challenged by third parties.
Generic products may be launched at risk and our patents may be revoked, circumvented or found not to be infringed.
For more information, please see Risk from page 220.
Many of our products are subject tochallenges by third parties.
Details of material challenges by third parties can be found in Note 29 to the Financial Statements from page 196.
Theexpiry dates shown below include granted SPC PTE and or Paediatric Exclusivity periods as appropriate.
In Europe, the exact SPC situation may vary by country as different Patent Offices grant SPCs at different rates.
Expiry dates in red relate to new molecular entity patents, the remaining dates relate to other patents.
The expiry dates of relevant regulatory data exclusivity periods are not represented in the table below.
Anumber of our products are subject to generic competition in one or more markets.
Aggregate Revenue for China, Japan 2 US and Europe Product Sales $m Product Sales $m Key marketed 1 products Description US China EU Japan 2018 2017 2016 2018 2017 2016 3 4 4 Atacand An angiotensin II antagonist for the 1st line expired expired 13 19 36 62 86 97 candesartan treatment of hypertension and symptomatic cilexitil heart failure Bevespi A combination of a long-acting muscarinic 2030-2031 2030 2030 2030 33 16 2 Aerosphere antagonist LAMA and a long-acting glycopyrrolate beta2-agonist LABA used for the long-term formoterol maintenance treatment of airflow obstruction in COPD 5 Brilinta An oral P2Y12 platelet inhibitor for acute 2018-2024, 2018, 2018-2024, 2023-2024, 588 509 348 532 402 347 6 8 9 Brilique coronary syndromes ACS ticagrelor 90mg or 2021-2030 2019, 2021 -2027 2025-2030 7 ticagrelor continuation therapy in high-risk patients 2021 ticagrelor 60mg with a history of myocardial infarction MI Bydureon A once-weekly injectable glucagon-like 2018-2028, 2020-2028, 2018-2028, 2018-2028, 475 458 463 85 93 109 10 10 10 10 Bydureon peptide-1 GLP-1 receptor agonist available as 2030 2029 2029 2029 BCise a single-dose tray, a single-dose pen or exenatide XR autoinjector device indicated as monotherapy injectable and as part of combination therapy adjunct to suspension diet and exercise to improve glycaemic control in adults with type-2 diabetes 11 Byetta A twice-daily injectable GLP-1 receptor agonist 2018-2020 2020 2018-2021 2018-2020 74 114 164 34 39 62 exenatide indicated to improve glycaemic control in adults injection with type-2 diabetes Calquence A selective inhibitor of Bruton's tyrosine kinase 2026-2032, 2032 2032 2032 62 acalabrutinib indicated for the treatment of mantle cell 2036 lymphoma MCL and in development for the treatment of multiple B-cell malignancies and other cancers 12 Crestor A statin for dyslipidaemia and 2018-2022 2020-2021 2020 2023 170 373 1,223 825 1,528 1,698 rosuvastatin  calcium 13 Daliresp An oral phosphodiesterase-4 inhibitor for 2020, 2023 2019, 155 167 134 28 26 15 Daxas adults with severe COPD to decrease their 2023-2024 2023 roflumilast number of exacerbations Duaklir A fixed-dose combination of a LAMA and a 2020, 2025, 2020, 2025, 2025, 91 77 62 14 aclidinium LABA for the maintenance treatment of COPD 2022-2029 2022-2027 2022-2029 2021-2029 formoterol Fasenra A monoclonal antibody for add-on maintenance 2020, 2021, 2020, 2020 218 77 benralizumab treatment of patients with severe asthma aged 2028-2034 2028 2028 12 years and older, and with an eosinophilic phenotype, which directly targets and depletes eosinophils by recruiting natural killer cells and inducing apoptosis programmed cell death 15 Faslodex An injectable oestrogen receptor antagonist.
2021 2021 2026 537 492 438 382 352 311 fulvestrant Used for the treatment of hormone receptor positive advanced breast cancer that has progressed following treatment with prior endocrine therapy Farxiga A selective inhibitor of human sodium-glucose 2020, 2025, 2020-2023, 2020-2027 2024-2025, 591 355 358 394 245 175 Forxiga co-transporter 2 SGLT-2 inhibitor indicated as 2020-2030 2028 2028 dapagliflozin monotherapy, and as part of combination therapy, adjunct to diet and exercise to improve glycaemic control in adult patients with type-2 diabetes Fluenz Tetra A live attenuated vaccine indicated for active 2018-2026 2020-2025 2020-2026 2020-2025 15 33 91 76 65 FluMist immunisation for the prevention of influenza Quadrivalent disease caused by influenza A subtype viruses live attenuated and type B viruses contained in the vaccine influenza vaccine AstraZeneca Annual Report & Form 20-F Information 2018 Patent Expiries of Key Marketed Products 217 Patent Expiries of Key Marketed Products continued Aggregate Revenue for China, Japan 2 US and Europe Product Sales $m Product Sales $m Key marketed 1 products Description US China EU Japan 2018 2017 2016 2018 2017 2016 Imfinzi A human monoclonal antibody that blocks 2030 2030 2030 2030 564 19 62 durvalumab PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumours immune-evading tactics and inducing an immune response.
It is currently indicated for the treatment of locally advanced or metastatic urothelial carcinoma and unresectable stage 3 non-small cell lung cancer NSCLC 16 17 Iressa An epidermal growth factor receptor-tyrosine 2023 2019, 2018, 26 39 23 376 367 358 gefitinib kinase inhibitor EGFR-TKI that acts to block 2023 2023 signals for cancer cell growth and survival in advanced NSCLC 19 Komboglyze Combines saxagliptin and metformin as either 2023, 2021, 2025 2021-2026, 111 145 18 Kombiglyze XR Komboglyze a twice-daily tablet for type-2 2025 2025 saxagliptin diabetes, or Kombiglyze XR an extended metformin release once-daily tablet for type-2 diabetes Lokelma An insoluble, non-absorbed sodium zirconium 2019, 2033 2032 2032-2033 sodium silicate, formulated as a powder for oral 2032-2033, zirconium suspension, that acts asa highly-selective 2035 cyclosilicate potassium-removing agent for the treatment of hyperkalaemia Lumoxiti A CD22-directed cytotoxin and a first-in-class 2022-2024, 2031 2022, 2031 2031 moxetumomab treatment in the US for adult patients with 2031-2032 pasudotox-tdfk relapsed or refractory hairy cell leukaemia HCL Lynparza An oral poly ADP-ribose polymerase PARP 2022-2024, 2021-2024, 2021-2029, 2021-2029, 345 141 127 250 130 81 olaparib inhibitor that may exploit tumour DNA damage 2028, 2024-2027, 2024-2027, 2024-2027, 20 20 20 20 response DDR pathway deficiencies to 2029, 2029, 2029, 2029, potentially kill cancer cells.
It is indicated for the 2024-2031 2024 2024 2024 treatment of women with BRCAm ovarian cancer and metastatic breast cancer Movantik A once-daily, peripherally acting mu-opioid 2022-2027, 2024, 2031 2022-2024, 2022-2024, 108 120 90 2 21 Moventig receptor antagonist approved for the treatment 2028, 2032 2029, 2031 naloxegol of opioid-induced constipation OIC in adult 2031 patients.
The indication varies by jurisdiction 22 Nexium A proton pump inhibitor used to treat 2018-2020 2018-2019 2018 2018, 287 499 526 955 973 975 esomeprazole acid-related diseases 2018-2019 19 Onglyza An oral dipeptidyl peptidase 4 DPP-4 inhibitor 2023, 2028 2021, 2025 2024, 2025 109 209 231 95 114 120 saxagliptin for type-2 diabetes 23 24 24 24 Pulmicort An inhaled corticosteroid for maintenance 2018-2019 2018 2018 2018 116 156 174 975 847 732 budesonide treatment of asthma Qtern A once-daily oral treatment combination of 2020, 2025, 2020-2023 2020-2027 2024-2025 4 5 dapagliflozin dapagliflozin 10mg and saxagliptin 5mg 2020-2029 saxagliptin indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin Seloken A beta-blocker once-daily tablet for control of expired expired expired expired 39 37 95 488 470 462 Toprol-XL hypertension, heart failure and angina metoprolol succinate 25 26 Seroquel XR Generally approved for the treatment of expired expired expired 73 175 515 70 82 134 quetiapine schizophrenia, bipolar disorder, major depressive disorder and, on a more limited basis, for generalised anxiety disorder 27 28 28 28 Symbicort A combination of an inhaled corticosteroid and a 2019-2029 2018 2018-2019 2019-2020 862 1,099 1,242 1,220 1,201 1,276 budesonide fast onset LABA for maintenance treatment of formoterol asthma and COPD either as Symbicort Turbuhaler or Symbicort pMDI pressurised metered-dose inhaler 218 AstraZeneca Annual Report & Form 20-F Information 2018 Additional Information Additional Information Aggregate Revenue for China, Japan 2 US and Europe Product Sales $m Product Sales $m Key marketed 1 products Description US China EU Japan 2018 2017 2016 2018 2017 2016 Synagis A humanised mAb used to prevent serious 2023 2023 2023 287 317 325 377 370 352 palivizumab lower respiratory tract disease caused by respiratory syncytial virus RSV in paediatric patients at high risk of acquiring RSV disease Tagrisso An EGFR-TKI indicated for patients with 2032 2032 2032 2034 869 405 254 808 486 158 osimertinib metastatic EGFR T790M mutation-positive NSCLC Tudorza Eklira A LAMA for the maintenance treatment of 2020, 2025, 2020, 2025, 2025, 25 66 77 75 74 84 Genuair COPD 2022-2029 2022-2027 2022-2029 2021-2029 aclidinium Xigduo Xigduo Combines dapagliflozin and metformin as either 2020, 2020-2023 2020-2028 2024-2025, 114 134 99 83 58 37 XR Xigduo a twice-daily tablet to improve 2025, 2030 dapagliflozin glycaemic control in adult patients with type-2 2020-2030 metformin diabetes who are inadequately controlled on metformin alone or XigduoXR an extended release once-daily tablet to improve glycaemic control in adult patients with type-2 diabetes who are inadequately controlled on metformin alone 29 Zoladex A luteinising hormone-releasing hormone 2022 2021 2021 2021 8 15 35 508 483 498 goserelin LHRH agonist used to treat prostate cancer, acetate implant breast cancer and certain benign gynaecological disorders Date represents expiry of a pending SPC PTE and or Paediatric Exclusivity period.
1 Expiry in major EU markets.
2 The Product Sales reflected are for Europe Region as defined in Market definitions on page 239.
5 Separate settlements with ANDA challengers for a licensed entry date corresponding to the expiry of US Patent No.
6 The patent was invalidated during invalidation proceedings at the Chinese Patent Office CNIPA.
In December 2018, however, the Beijing High Peoples Court vacated the invalidation decision and remanded the case back to the CNIPA for further processing in view of the Courts decision upholding the validity of the patent.
7 The patent was invalidated during invalidation proceedings at the CNIPA.
The patentee has appealed that decision.
8 The patent was revoked during opposition proceedings at the European Patent Office EPO.
9 The patent is the subject of a pending opposition proceeding at the EPO.
10 Patent expiry date relates to BCise.
11 Separate settlements with ANDA challengers for a licensed entry date of 15 October 2017, or later, subject to regulatory approval.
12 A settlement agreement in the US permitted Watson Laboratories, Inc. and Actavis, Inc. together, Watson to begin selling its generic version of Crestor and its rosuvastatin zinc product from 2May 2016.
13 There is eight years data exclusivity and two years market exclusivity for Daxas in the EU to 5 July 2020.
15 Settled with various generic companies for licensed entry dates of 25 March 2019 or later.
16 In the US, Iressa has seven years Orphan Drug exclusivity to 13 July 2022.
There is eight years data exclusivity and two years market exclusivity for Iressa in the EU to 24 June 2019.
18 Komboglyze KombiglyzeXR revenue is included in the Onglyza revenue figure.
19 AstraZeneca does not have commercialisation rights.
20 Patent expiry date relates to the tablet formulation.
21 ProStrakan Group a subsidiary of Kyowa Hakko Kirin is exclusively licensed in the EU, Iceland, Norway, Switzerland and Liechtenstein.
22 Licence agreements have allowed generic companies to launch generic capsule versions in the US.
23 A licence agreement with Teva permits its ongoing sale in the US of a generic version from December 2009.
The 2018 expiry relates to the Flexhaler device, while the 2019 expiry relates to the formulation in the Flexhaler presentation and also to Respules.
24 The 2018 expiry relates to the formulation in the Turbuhaler presentation and to a process useful for the Respules product.
25 Rights licensed to Luye Pharma.
27 Patent expiry dates relate to the Symbicort pMDI product, including any granted Paediatric Exclusivity term.
28 Patent expiry dates relate to the Symbicort Turbuhaler product.
AstraZeneca Annual Report & Form 20-F Information 2018 Patent Expiries of Key Marketed Products 219
